Farrerol Alleviates Cerebral Ischemia-Reperfusion Injury by Promoting Neuronal Survival and Reducing Neuroinflammation.

Ischemia-reperfusion (I/R) injury is a key influencing factor in the outcome of stroke. Inflammatory response, oxidative stress, and neuronal apoptosis are among the main factors that affect the progression of I/R injury. Farrerol (FAR) is a natural compound that can effectively inhibit the inflammatory response and oxidative stress. However, the role of FAR in cerebral I/R injury remains unknown. In this study, we found that FAR reduced brain injury and neuronal viability after cerebral I/R injury. Meanwhile, administration of FAR also reduced the inflammatory response of microglia after brain injury. Mechanistically, FAR treatment directly reduced neuronal death after oxygen glucose deprivation/re-oxygenation (OGD/R) through enhancing cAMP-response element binding protein (CREB) activation to increase the expression of downstream neurotrophic factors and anti-apoptotic genes. Moreover, FAR decreased the activation of nuclear factor kappa-B (NF-κB) and mitogen-activated protein kinase (MAPK) signaling pathways, inhibited microglia activation, and reduced the production of inflammatory cytokines in microglia after OGD/R treatment or LPS stimulation. The compromised inflammatory response by FAR directly promoted the survival of neurons after OGD/R. In conclusion, FAR exerted a protective effect on cerebral I/R injury by directly decreasing neuronal death through upregulating CREB expression and attenuating neuroinflammation. Therefore, FAR could be a potentially effective drug for the treatment of cerebral I/R injury.

Joint Resource Allocation for Multiuser Opportunistic Beamforming Systems with OFDM-NOMA.

Opportunistic beamforming (OBF) is an effective technique to improve the spectrum efficiencies (SEs) of multiple-input-multiple-output (MIMO) systems, which can obtain multiuser diversity gains with both low computation complexity and feedback information. To serve multiple users simultaneously, many multiple-access schemes have been researched in OBF. However, for most of the multiple-access schemes, the SEs are not satisfactory. To further improve the SE, this paper proposes a downlink multiuser OBF system, where both orthogonal frequency division multiplexing (OFDM) and non-orthogonal multiple-access (NOMA) methods are applied. The closed-form expressions of the equivalent channels and SE are derived in frequency selective fading channels. Then, an optimization problem is formulated to maximize the SE, although the optimization problem is non-convex and hard to solve. To obtain the solution, we divide the optimization problem into two suboptimal issues, and then a joint iterative algorithm is applied. In the proposed optimization scheme, the subcarrier mapping ϑ, user pairing knc and allocated power Pknc are determined to maximize spectrum efficiency (SE) and reduce bit error ratio (BER). According to numerical results, the proposed method achieves approximately 5 dB gain on both SE and BER, compared to the existing beamforming methods with low feedback information. Moreover, the SE of the proposed method is approximately 2 (bps/Hz) higher than sparse code multiple-access (SCMA), when the number of waiting users and the ratio of transmit power to noise variance are respectively 10 and 20 dB. It is indicated that the proposed scheme can achieve high and low BER with the limited feedback and computation complexity, regardless of the transmit power and the number of waiting users.

Shikonofuran E plays an anti-inflammatory role by down-regulating MAPK and NF-κB signaling pathways in lipopolysaccharide-stimulated RAW264.7 macrophages.

The anti-inflammatory effects of shikonofuran E from Onosma paniculatum on RAW 264.7 murine macrophage cells induced by lipopolysaccharide (LPS) were first time examined. A series of non-cytotoxic concentrations of shikonofuran E (< 10 µM) treatments were found to reduce the accumulation of pro-inflammatory cytokine, including tumor necrosis factor-α (TNFα), interleukin-6 (IL-6), interleukin-1ß (IL-1ß), and inhibit the expression of nitric oxide synthase (iNOS) and cyclooxidase-2 (COX-2) in the LPS-stimulated macrophages as compared to the LPS-only treated cells. Nitric oxide (NO) production was also significantly suppressed in a dose-dependent manner (P < 0.05) with an IC50, the phosphorylation level of JNK of 3.5 µg/mL. In the anti-inflammatory pathway studies, ERK, p38 and IκBα were also decreased by shikonofuran E at 10 µM, in spite of the total levels of the MAPK isoforms and IκBα did not differ significantly. Our results indicate that shikonofuran E could exert an anti-inflammatory effect on LPS-induced RAW264.7 cells by down-regulating MAPK and NF-κB signaling pathways and regulating a series of cytokine production in lipopolysaccharide-stimulated RAW264.7 macrophages.